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ABSTRACT  
Introduction: Brivaracetam (BRV) is a new AED currently licensed for the adjunctive 
treatment of adult patients with focal epilepsies. It is a ligand of the ubiquitous synaptic 
vesicle glycoprotein 2A (SV2A). 
Areas covered: This paper covers the preclinical and subsequent clinical development of 
BRV focusing on the discovery of the SV2A protein as the main target for levetiracetam 
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(LEV) and the main similarities and differences between LEV and BRV in terms of 
pharmacodynamic and pharmacokinetic properties. Phase II and Phase III studies are also 
presented and data from post-marketing phase IV studies are discussed.  
Expert opinion: The preclinical development of BRV is quite unique and has raised several 
doubts on current methodologies adopted for AED development, reinforcing the need for new 
approaches. The preclinical and clinical profile suggest that BRV is potentially an ideal 
compound in the emergency setting given the rapid onset of action associated with being 
water soluble and, therefore, available in intravenous formulation. In addition, data from 
Phase III studies have already suggested that BRV may be effective not only in focal 
epilepsies but also in generalised syndromes. Further data from special populations such as 
children and women of child bearing age are urgently needed.  
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Article Highlights: 
 The discovery of the SV2A protein and the subsequent development of BRV have further 
confirmed the need for new and innovative preclinical models of epilepsy 
 The preclinical and clinical profile of BRV suggest that it is probably the ideal AED to be 
used in an emergency setting but data on treatment of status epilepticus are currently just 
anecdotal  
 Emerging data are suggesting that the overnight conversion from LEV to BRV is not only 
safe and well tolerated but may provide further benefits in terms of tolerability especially 
in patients with paradoxical sedation from LEV or behavioural adverse events.  
 Data from preclinical and Phase III and IV studies are also suggesting that BRV may be 
effective also in primary generalised syndromes  
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 Data from special populations such as children and women of child baring age are 
urgently needed 
 
1. INTRODUCTION  
 Epilepsy is one of the most common neurological conditions with incidence rates, in 
high-income countries, ranging between 40 and 70/100,000 persons/year [1]. Over 50 million 
people worldwide suffer from epilepsy with an overall health burden accounting for 0.5% of 
the total burden of diseases [2]. About two thirds of people with epilepsy become seizure free 
on current treatments but despite the introduction of several antiepileptic drugs (AEDs), one 
third of patients are still uncontrolled [3]. It is, therefore, evident that continuous research is 
needed in order to have new compounds.  
Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidinyl] butanamide; UCB 34714; BRV), is a 
new AED currently licensed for the adjunctive treatment of focal epilepsies [4] (Figure 1). It 
is a ligand of the ubiquitous synaptic vesicle glycoprotein 2A (SV2A) [5]. The SV2 protein is 
a prototype protein present in the synaptic vesicles of neurons and endocrine cells [6,7], 
possess a 12-transmembrane-spanning structure and consists of three isoforms, SV2A, SV2B 
and SV2C. Among SV2 isoforms, SV2A is highly expressed in all brain areas including the 
cerebral cortex, hippocampus and cerebellum [6,8] but it is also expressed by neuroendocrine 
cells and neuromuscular junctions [9] and previous studies have suggested that SV2A 
regulates synaptic vesicle exocytosis and presynaptic neurotransmitter release [10,11].  
The discovery and preclinical development of BRV is strictly interlinked with that of the 
SV2A protein and the discovery of levetiracetam (LEV) as the first AED showing to bind the 
SV2A protein. In preclinical studies, LEV displayed protective effects against audiogenic and 
kindled seizures, 6-Hz electrical seizures [12] and spike-wave discharges in genetic models 
of absence epilepsy [13,14] but showed not to be effective in standard animal models used for 
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AED discovery, namely the maximal electroshock (MES) and pentylenetetrazol (PTZ) tests 
[15]. This preclinical profile of LEV correlated well with the broad-spectrum clinical efficacy 
shown by clinical studies [16] but the atypical antiepileptic properties suggested that LEV 
possessed a novel mechanism of action different from that of conventional AEDs [15]. 
Binding studies subsequently revealed a reversible, saturable, and stereoselective binding to 
the SV2A protein [11], resulting in a reduced exocytosis of synaptic vesicles and an increased 
induction of rate depression at excitatory synapses during epileptic activity [17]. Since then, 
research focused on the discovery of new agents targeting the SV2A protein that ultimately 
led to the development of BRV.  
This is a narrative review aimed at providing a comprehensive overview of the preclinical 
discovery and subsequent clinical development of BRV. References were identified by 
searches of Medline/PubMed until May 2017 using the key word “Brivaracetam”. Only 
papers published in peer-reviewed journals were included. Additional publications were hand 
searched if relevant to the discussion. 
 
2. DISCOVERY STRATEGY AND PRECLINICAL DEVELOPMENT  
 A number of animal studies suggested that the SV2A protein was a potentially good 
target for seizure control. SV2A knockout mice fail to grow and develop spontaneous 
seizures leading to death within 2-3 weeks after birth while heterozygous SV2A knockout 
mice do not show spontaneous seizures, but rather pro-epileptic traits such as enhanced 
susceptibility to the proconvulsant effect of pilocarpine and kainate, a decreased 6-Hz seizure 
threshold and an enhanced rate of corneal kindling [18,19]. Studies of cultured neurons from 
SV2A knockout mice demonstrate a reduced postsynaptic response due to a lower initial 
vesicle release probability and a decrease in neurotransmitters release during stimulation 
[20,21]. Furthermore, expressional and functional changes in SV2A are found in animal 
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models of epileptogenesis [22,23] and in brain tissue obtained from patients with epilepsy 
[24–26] suggesting that decreased SV2A expression/functioning contributes to the 
progression of epilepsy [8]. SV2A binding strongly correlates with the antiepileptic efficacy 
in different preclinical models of epilepsy like the audiogenic seizure-prone mice [11,19] and 
decreased levels of SV2A appear to be involved in the mechanisms underlying drug-resistant 
epilepsy [8]. All these evidence taken together strongly suggest that the SV2A protein has a 
clear involvement in the pathogenesis of epilepsy and can, therefore, play a role in its 
treatment; however, detailed functions and mechanisms (e.g. neurotransmitter specificity) of 
SV2A is still unclear [8]. 
 As already mentioned, the discovery of the SV2A as the main molecular target of 
LEV and the subsequent evidence suggesting a potential role in the treatment of epilepsy, 
have led to the design of a major drug discovery program with the purpose of optimizing the 
therapeutic benefit of the SV2A mechanism. The goal was to identify selective and more 
potent SV2A ligands providing a more complete seizure suppression than LEV [27]. 
Approximately 12,000 compounds were screened in vitro for SV2A binding affinity; 1,200 
were further screened in vivo for seizure protection in audiogenic seizure-susceptible mice, 
and about 30 compounds were selected and largely characterized in different animal models 
of seizures and epilepsy [27]. These studies indicated that substitution on the 4-position of the 
pyrrolidine ring of LEV could enhance binding affinity. In this systematic investigation of 
substitutions at this site, various small hydrophobic groups were found to confer increased 
affinity to SV2A as compared to LEV and an enhanced activity in the audiogenic seizure test 
[27]. Among the analogues with enhanced binding affinity, BRV, a 2-pyrrolidone derivative 
structurally related to LEV with a molecular weight of 212, was selected as a candidate for 
drug development [27].  
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BRV is a highly selective and reversible ligand of the SV2A with an affinity and ability to 
inhibit synaptic transmission and vesicle release that is superior to LEV.  Furthermore, results 
from SV2A knockout mice show that up to the concentration of 600 nM (the highest 
concentration tested), [3H]BRV is highly selective, labelling the SV2A protein only [28,29]. 
The in vitro binding of [3H]BRV in rat and human brain shows that, similarly to LEV, BRV 
displays identical affinity for rat and human SV2A (Kd of 62 nM) [30,31]; however, BRV 
shows an about 15-30 fold higher affinity than LEV for the presynaptically located SV2A 
that actually corresponds to a higher efficacy in the animal models of epilepsy and in studies 
with human brain slices than the post-synaptic SV2A [30,32].   
At therapeutically relevant doses, BRV occupies 80% to >90% of SV2A in the brain [33]. Ex 
vivo binding experiments in the mouse brain shows that BRV reaches maximal SV2A 
occupancy within 5 to 15 min after administration, a time range that also displays maximal 
protection against seizures [34]. Studies in vitro in human cells revealed that BRV has a 
higher lipophilicity (LogD 1.04) than LEV (LogD -0.64) resulting in a more rapid brain 
penetration that is paralleled by a faster onset of seizure protection in an audiogenic mouse 
model of seizures [35,36]. A seven-fold difference was observed in brain entry speed, with 
BRV having a predicted drug entry half-time of only 3 min against the almost 23 min of LEV 
[35]. Likewise, ex vivo binding studies in the same audiogenic mouse model showed 
maximal SV2A occupancy and maximal activity within 5–15 min following intraperitoneal 
(i.p.) dosing with BRV, compared to 30–60 min for LEV [30]. Therefore, this more rapid 
entry into the brain of BRV correlates with a shorter latency of action that may be clinically 
relevant in the treatment of emergencies such as status epilepticus or seizures clusters 
[37,38]. 
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Rat hippocampal slice studies comparing BRV and LEV using high-frequency neuronal 
stimulation, demonstrate that BRV augments synaptic depression and thereby decreases 
synaptic transmission at 100-fold lower concentrations than LEV. Additionally, BRV is more 
effective than LEV in reducing synaptic vesicle mobilization [39].  
BRV has shown a low therapeutic index (ratio between the TD50 of motor impairment on the 
rotarod test in fully kindled animals and the ED50 for seizure protection against generalized 
motor seizures the same animals) but still more favourable than LEV (46 and 148, 
respectively). In the rotarod test in amygdala-kindled rats BRV has a higher therapeutic index 
than LEV (4 and 2, respectively). Nevertheless, it was noticeably higher than that observed 
for classical and other newer AEDs (therapeutic indexes ranging from 2 to 21) [32]. 
In comparison to LEV, BRV lacks any direct activity on inhibitory and excitatory receptors 
including AMPA, glycine, and GABA-A with the exception of a weak inhibition of the 
NMDA receptor mediated currents at very high concentrations, which will likely be not 
relevant at therapeutic doses [40] (Table 1). Although BRV shares with LEV an ability to 
oppose the action of negative modulators on the two main inhibitory receptors, namely 
GABA-A and glycine, this finding has been thought not to be clinical relevant but further 
studies are needed [40]. Studies exploring other potential mechanisms demonstrate that BRV 
has no effect on high and low voltage–activated calcium channels [28] or on voltage-gated 
potassium currents in isolated rat hippocampal neurons at therapeutically relevant 
concentrations. Some authors suggest that BRV, as opposed to LEV, inhibits voltage-
dependent sodium channels in rats’ primary cortical neurons in culture [41] but other studies 
do not replicate these findings and demonstrate a substantial lack of effect of BRV in 
reducing the neuronal firing mediated by a blockade of voltage-gated sodium channels [42]. 
In particular, some studies investigate the effect of BRV on voltage-gated sodium currents in 
comparison to carbamazepine (CBZ) in different cell systems (i.e. neuroblastoma cells, rat 
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cultured cortical neurons, CA1 neurons from mouse hippocampal slice) in order to explore 
the potential efficacy of BRV in reducing sustained repetitive firing [42]. These studies seem 
to suggest that BRV inhibits voltage-gated sodium currents in mouse neuroblastoma cells and 
in rats’ primary cortical cultures, but not in CA1 pyramidal neurons of adult mice and does 
not reduce sustained repetitive firing induced in native or cultured neurons. These findings 
suggest that none of the antiepileptic properties of BRV are mediated by a CBZ-like blockade 
of voltage-gated sodium channels [42]. This is anyway in agreement with the protective 
effects of BRV against MES occurring only at supratherapeutic doses [28].  
In vitro studies show that BRV possesses higher potency and efficacy than LEV against 
epileptiform responses in two different in vitro rat hippocampal slice models of epilepsy in a 
dose range which is relevant for its clinical efficacy [32,43]. The increased affinity of BRV 
for the SV2A as compared to LEV well correlates with the markedly higher increased 
potency for seizure protection observed in different in vivo models of epilepsy [32]. The 
efficacy of BRV has been studied in both partial and generalized seizure models including 
audiogenic mice, Genetic Absence Epilepsy Rats from Strasbourg (GAERS), amygdala and 
corneal kindling models [27,32] and in a rat model of post-hypoxic myoclonus [44]. In these 
models, BRV consistently demonstrates a more potent and complete seizure suppression than 
LEV [32,45]. In particular, in amygdala-kindled mice, BRV (6.8–210 mg/kg) dose-
dependently reduces seizure severity, with nearly complete suppression of seizures observed 
at the highest tested dose. In contrast, LEV (17-540 mg/kg) provides only limited protection 
even at high doses [28,32]. BRV also produces a more complete suppression of motor seizure 
severity and after-discharge duration than LEV in fully amygdala-kindled rats; in particular, 
BRV induces an important suppression in motor-seizure severity from a dose of 21.2mg/kg, 
while LEV produces an analogous effect from a dose of 170mg/kg. BRV also significantly 
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decreases the after-discharge duration at the highest dose tested (212.3mg/kg), whereas LEV 
has no effects on this parameter up to 1700mg/kg [32,45]. 
Similarly, another study demonstrates the efficacy of BRV (0.68, 2.1, 6.8 or 21 mg/kg) in the 
amygdala-kindling model of temporal lobe epilepsy [46]. The focal seizure threshold (ADT) 
was significantly increased by BRV at 0.68 and 21 mg/kg, but not at intermediate doses 
showing an effect not entirely dose-dependent. Instead, seizure severity recorded at the focal 
seizure threshold was dose-dependently decreased by BRV. In addition, the most marked 
anticonvulsant effect of BRV was determined by significant increase, at all doses and in a 
dose-dependent fashion, of the generalized seizure threshold (GST). 
In audiogenic seizure-susceptible mice, BRV provides more potent and complete protection 
from clonic convulsions than LEV (ED50 values = 2.4 vs. 30 mg/kg, i.p.) [32].  
In the GAERS model of absence epilepsy, BRV exerts a more complete suppression of 
spike–wave discharge (SWDs) than LEV. BRV significantly suppresses spontaneous SWDs 
in GAERS rats from a dose of 2.1mg/kg with complete inhibition appearing at the highest 
tested dose (67.9mg/kg). In contrast LEV induces significant suppression of SWDs from a 
dose of 5.4mg/kg but does not attain complete inhibition, even at the highest tested dose 
(170mg/kg) [13,14,32]. 
BRV also differs from LEV in its ability to protect against seizures induced by the maximal 
electroshock (MES) and PTZ seizure tests; BRV, administered i.p. 30 min before seizure 
induction in mice, protects against clonic convulsions induced by PTZ and against tonic hind 
limb extension induced by MES in mice, although with higher ED50 values (ED50 values = 30 
(PTZ) and 113 (MES) mg/kg, i.p.) [32,47]. 
In a rat model of post-hypoxic myoclonus, BRV (0.3mg/kg, the minimal effective dose) 
shows a 10-fold higher potency than LEV (3mg/kg, the minimal effective dose) against 
myoclonus and generalized seizures [44].  
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BRV has also shown potent anticonvulsant effects in animal models of partially drug-
resistant such as the self-sustaining status epilepticus (SSSE) and 6-Hz seizures in mice, 
supporting its potential efficacy in treatment-resistant epilepsy [40]. The SSSE rat model is 
characterized by stimulation of excitatory pathways that can create reverberating limbic 
circuits in which seizures are self-sustaining and thereby inducing damage to the brain. This 
process, once set in motion, is refractory to standard anticonvulsants such as diazepam and 
phenytoin [44]. BRV (20 and 300 mg/kg, i.v.) reduces the total duration of seizures in this 
model to 11% and 0.8% of vehicle-treated controls, respectively, while LEV (200 mg/kg) 
reduces to 35% of control. The combination of BRV and diazepam has demonstrated a 
synergistic action in decreasing the duration of active seizures to 3% of controls, which 
suggests a potential potent anticonvulsant activity in status epilepticus [49]. Furthermore, in 
addition to the acute short-term effect on SSSE, BRV also reduces the number of chronic 
spontaneous recurrent seizures occurring both 6 weeks and 1 year after treatment. This seems 
to suggest that BRV has not only anticonvulsant effects but may also have disease-modifying 
properties in refractory SSSE rats. However, this effect needs to be confirmed also in other 
models and might be due to its effects on acute SE seizures. 
Studies using a newly developed 6-Hz corneal-kindling model in mice confirmed the high 
potency and efficacy of BRV against both partial and secondarily generalized seizures [40]. 
In corneally kindled mice, a model of partial epilepsy, BRV protects animals from 
secondarily generalised seizures at concentrations several-times lower than those of LEV 
(ED50 = 1.2 vs. 7.3 mg/kg, i.p.) [40]. In the same corneal kindling model, pre-treatment with 
BRV, prior to corneal stimulation, leads to suppression of kindling development at doses 10 
times lower than those of LEV (0.21-6.8 mg/kg vs. 1.7-54 mg/kg, i.p.). In addition, continued 
corneal stimulations following cessation of treatment and a wash-out period, results in a 
significant and persistent reduction in the incidence of generalized motor seizures in the 
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group previously treated with the highest dose of BRV (6.8 mg/kg); an effect that was not 
observed in any animal pre-treated with LEV [40]. This reduction in previously BRV-treated 
groups can certainly be due to the enhanced affinity of BRV for SV2A, compared to that of 
LEV [32] and further supports the hypothesis of possible disease-modifying properties of 
BRV.  
The higher efficacy of BRV as compared to LEV in several animal models of epilepsy could 
be also due to individual differences in the interaction with the SV2A protein [50]. In fact, 
studies with an SV2A allosteric modulator demonstrate that the interaction of BRV with 
SV2A differs from that of LEV, likely inducing or stabilizing different SV2A protein 
conformations which may provide the molecular rationale for their distinct pharmacodynamic 
properties of BRV as compared to LEV [51]. Actually, LEV and BRV act at different binding 
sites or interact with different conformational states of the SV2A protein [50]. This probably 
explains findings from electrophysiological studies in rat hippocampal slices showing a 
greater ability of BRV to inhibit synaptic transmission and vesicle release [28,39,50].  
Interestingly enough, recent studies suggested an age-dependent antiepileptogenic effect of 
BRV (10 and 100 mg/kg) at different ages in rats (P14, P21, P28, and P60) in a rapid kindling 
model measured by an increase of after-discharge threshold (ADT) [47]. BRV, at the dose of 
100 mg/kg, significantly increases ADT at all ages, while, at the dose of 10mg/kg, was 
effective in increasing ADT in P60, P28, and P21 rats only. BRV also reduces the after-
discharge duration, and data indicate that 10 and 100 mg/kg doses of BRV are significantly 
effective at P60, whereas only the 100 mg/kg dose is effective at P21. At P60, the 
administration of BRV determines an increased number of stimulations to reach stage 4-5 
seizures in a dose-dependent manner and significantly reduces the number of stage 4-5 
seizures at 100 mg/kg. Likewise, at P28 and P21, the administration of BRV determines the 
almost complete abolition of stage 4-5 seizures and determines a higher number of 
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stimulations to develop stage 4-5 seizures in a dose-dependent manner. Thus, BRV displays a 
dose-dependent anti-ictogenic effect with consistent efficacy from P14 to P60 in the rapid 
kindling model and such an effect may be age-dependent [47] and this may be due to 
developmental differences in SV2A expression. In fact, the expression of the SV2A is age-
dependent, with lower levels in younger animals. In rat hippocampus, SV2A expression is 
lower at P14 than at P21 and P40 [52,53]; this reduced SV2A expression at P14 may explain 
the lack of antiepileptogenic effects of BRV at this age, despite the presence of an 
anticonvulsant effect [47].  
In conclusion BRV seems to possess properties superior to LEV as both an antiepileptic and 
antiepileptogenic agent in many experimental models of epilepsy. This profile has triggered 
the decision to focus on BRV for further clinical development. 
 
3. PHARMACOKINETICS OF BRIVARACETAM 
The pharmacokinetics of BRV was initially studied in healthy volunteers in two Phase 
I randomized, double-blind, placebo-controlled trials [54,55] and subsequently in patients 
with epilepsy, and subjects with hepatic or renal impairment [56,57]. 
In healthy adults, BRV exhibits a linear and dose-dependent pharmacokinetic profile over a 
broad range of doses (single doses: 10–1400 mg; multiple doses: 200–800 mg daily) with low 
interindividual variability [54,55]. After oral administration, BRV is rapidly and almost 
completely absorbed with a tmax between 1 and 2h, nearly identical to LEV tmax (0.5 -1h), with 
low coefﬁcients of variation of Cmax (<25%), between 10 and 1400 mg for BRV or 1500 mg 
for LEV, when given in a single dose [54,58]. Steady-state is reached after 2 days and 
similarly to LEV, BRV has an almost 100% bioavailability [54,59] (Table 2). Food may 
decrease the absorption of BRV but has no effect on its pharmacokinetics. In fact, a high-fat 
meal prolongs tmax by 3 h and reduces Cmax by one-third, but does not affect the area under 
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the curve (AUC) [54]. BRV is highly water soluble and distributes over the total volume of 
body water. The volume of distribution of BRV is 0.6 L/kg, slightly lower than total body 
water [54,59]. Protein binding is low for both BRV (<20%) and LEV (<10%). BRV is highly 
water soluble and easily crosses mucous membranes as shown by very similar saliva and 
plasma levels. This obviously suggests that saliva could be a suitable sample for monitoring 
BRV plasma concentrations when blood samples are unavailable [55]. As already mentioned, 
BRV has a fast onset of action and the pharmacological peak activity and peak plasma levels 
occur simultaneously, after a single oral dose. On the contrary, LEV maximum 
pharmacological activity follows maximum plasma concentrations by almost 1 h. This is due 
to the high lipophilicity of BRV that enables a rapid brain penetration [35].   
Renal clearance of BRV is as low as 0.06 mL/min/kg (whereas the metabolites have a high 
renal clearance) [55]. BRV is eliminated by renal excretion within 72 h, about 5–8% 
unchanged and >90% as pharmacologically inactive metabolites suggesting predominantly 
metabolic clearance [4,5,45,54,59]. In fact, BRV is extensively metabolized through two 
main metabolic pathways, namely hepatic hydrolysis of the acetamide group, mediated by 
CYP2C8, and to a lesser degree by the isoforms CYP3A4 and CYP2C19 [59]. The two main 
metabolites in the human urine, (2-[2-oxo-4-propylpyrrolidin-1-yl]butyric acid (35%) and 2-
[2-oxo-4-propylpyrrolidin-1-yl]-4-hydroxy-butanamide (< 10%), are not pharmacologically 
active [59]. As already mentioned, the elimination of BRV is dependent on the activity of the 
CYP450 system and CYP2C8 induction can increase the hydroxylation of BRV and decrease 
the plasma concentrations by up to 50%, while CYP450 inhibitors may affect effective BRV 
concentrations to a lesser degree [40]. 
The metabolic clearance of BRV is increased in a time-dependent manner at supratherapeutic 
doses and the steady state is reached within a week of repeated administration. The half-life 
of BRV is approximately 7-8 h (range 7.26 - 8.18 h) and does not vary with the applied 
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doses, which allows twice-daily dosing [54,55,59]. Studies in patients with chronic liver 
disease show that, the total body clearance of BRV is reduced by 25% to 35% (0.04 per 
min/kg) and the plasma half-life is accordingly increased from 14.2 to 17.4 h. Unrelated to 
the degree of liver dysfunction, BRV blood levels are increased by 50% to 60%. In such 
patients, a reduction by one-third of the maximum daily dose of the drug is needed [45]. In 
patients with severe renal impairment (creatinine clearance <30 mL/min/1.73 m
2
), there are 
increased blood levels of  BRV (>20%) and increased levels of its metabolites [56,57]. 
Nevertheless, dose reduction is not required due to the inactivity and low toxicity of BRV 
metabolites [57].  
The pharmacokinetic profile of BRV in the elderly [54,57] or subjects with renal impairment 
[40] is similar to that observed in healthy subjects.  
A Japanese study investigated the role of CYP2C19 genotype on BRV metabolism in healthy 
subjects, showing a clearance reduced by 30% in poor metabolizers as compared to extensive 
CYP2C19 metabolisers [60]. Subjects with inactive mutations of the CYP2C19 show only 
minor reduction (29%) in BRV clearance, which is probably not clinically significant. Thus, 
individuals with CYP2C19 genetic polymorphisms do not require any dose adjustment [60].  
In terms of drug-drug interactions, there is no evidence of an inducing or inhibiting 
effect of BRV on CYP3A4 activity [61]. BRV adjunctive treatment does not affect plasma 
concentrations of concomitantly administered AEDs, except for plasma concentrations of 
carbamazepine-10,11-epoxide which increases during co-administration with BRV [40]. 
AEDs with inducing properties such as carbamazepine, phenytoin and 
phenobarbital/primidone reduce BRV plasma concentrations by 26%, 21%, and 19%, 
respectively, but this does not seem to be clinically significant and dose adjustments do not 
seem to be required [62,63]. Rifampin significantly decreases the AUC of BRV by 45%, 
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mostly through CYP2C19 induction, without significantly affecting the Cmax. Adjustment in 
BRV dose should be considered in patients on treatment with rifampin [64].  
A moderate reduction of the oestrogen and progesterone components of low-dose oral 
contraceptives is observed after BRV administration, but this does not seem to be clinically 
relevant  [40,45] and BRV concentrations are not affected by oral contraceptives [65].  At the 
supratherapeutic dose of 400 mg/day, BRV reduces plasma concentrations of oestrogen and 
progesterone components of contraceptives, but does not affect blood levels of endogenous 
hormones (LH, FSH, estradiol, and progesterone) during the menstrual cycle  [66]. 
  
4. CLINICAL DEVELOPMENT  
4.1 Brivaracetam for the adjunctive treatment of focal epilepsies 
 BRV has been initially investigated for the adjunctive treatment of adults with focal 
epilepsies in a number of Phase II and III studies. Two phase IIb studies investigated efficacy 
of BRV across different dosage. In study NO1193, patients 16-65 years are randomized 
(1:1:1:1) to placebo (PBO), BRV 5 mg/day, 20 mg/day, or 50 mg/day, administered BID 
without up titration during a 7-week treatment period. The primary efficacy endpoint (seizure 
frequency/week during the treatment period relative to placebo) was statistically significant 
only for BRV 50 mg/day but the secondary efficacy endpoint (≥50% responder rate and 
median per cent reduction from baseline in POS frequency/week) provided supportive 
evidence for the 20 mg/day [67]. A second study (N01114) mainly compared BRV at dosages 
of 50 and 150 mg/day and failed to show any difference against PBO for the primary efficacy 
endpoint [68]. For this reason four Phase III randomised, double blind studies have been 
subsequently completed [69–72]. Two studies used a fixed-dose design and included patients 
with focal epilepsy only [69,71], one study adopted a flexible dose design and enrolled also 
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patients with primary generalized seizures [72], the fourth study (NO1258) excluded patients 
exposed to LEV during the three months before visit 1 [70] (Table 3) .  
In study NO1252, the efficacy of BRV (20 mg, 50 mg, and 100 mg/day) was investigated 
against PBO in adult patients with uncontrolled focal seizures [71] but the primary efficacy 
end-point (per cent reduction over PBO in baseline-adjusted focal seizure frequency/week 
over the 12-week treatment period) was statistically significant only for BRV 100 mg/day 
[71,p.20]. In study NO1253, adult patients with uncontrolled epilepsy were randomized 
(1:1:1:1) to PBO or BRV 5 mg, 20 mg, or 50 mg/day without up titration [69]. The primary 
efficacy endpoint (per cent reduction over PBO in baseline-adjusted partial-onset seizure 
frequency/week during the 12-week treatment period) was statistically significant only for 
BRV 50 mg. In study NO1258, 768 patients were randomised to placebo, BRV 100 mg and 
BRV 200 mg respectively [70] and seizure reduction over placebo was 22.8% for BRV 100 
mg and 23.2% for BRV 200 mg. Finally, study NO1254 adopted a flexible-dose design in 
adult patients with uncontrolled epilepsy but up to 20% of subjects had generalized epilepsies 
[72]. Patients were randomized (3:1) to BRV or PBO and initiated at 20 mg/day and 
increased, as needed, up to 150 mg/day during an 8-week dose-finding period followed by 
another 8-week stable-dose maintenance period. During the 16-week treatment period, 
median per cent reduction from baseline in POS frequency/week was not statistically 
significant while 50% responder rate was 30.3% for BRV and 16.7% for PBO (p = 0.006). 
The relevance of this study is the suggested potential efficacy as adjunctive BRV in adults 
with generalized epilepsy [72]. 
 
 In terms of safety, all Phase IIb and Phase III studies reported no difference in 
treatment emergent adverse events (TEAEs) for patients treated with BRV as compared to 
PBO. TEAEs were usually mild to moderate in severity and mainly characterized by 
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headache, fatigue, nasopharyngitis, nausea, somnolence and dizziness. Phase IIb studies 
reported 2.6% for BRV (5-50 mg) [67] raising up to 67.3% for BRV 150 mg [68]. The two 
Phase III fixed-dose studies reported at least one TEAE in 56.6% to 79.0%, with a high 
proportion of completers (84.5% - 94.0%) and low discontinuation rates (4.0%-8.2%) 
[69,71]. These data are similar to those reported by the Phase III flexible-dose trial, where 
patients reporting at least one TEAE were in the region of 66.0% for BRV against 65.3% of 
PBO subjects [72]. The most commonly reported TEAEs leading to discontinuation in all 
studies were psychiatric adverse events (PAEs). Phase III studies reported a detailed account 
of PAEs represented mainly by aggression, anxiety, irritability, depression and insomnia 
[69,71]. However, PAEs were reported in a low proportion of patients (3.0%, 4.0%, and 3.0% 
for BRV 20 mg, 50 mg and 100 mg/day) [71] and were described as occurring no more 
frequently than with PBO: insomnia (BRV 4.0% vs. PBO 2.0%), depression (BRV 3.7% vs. 
PBO 1.0%), irritability (BRV 3.7% vs. PBO 2.0%), anxiety (BRV 1.7% vs. PBO 1.0%), 
agitation (BRV 1.0% vs. PBO 0%) and depressed mood (BRV 1.0% vs. PBO 0%) [69].  
Finally, one study investigated the potential impact of BRV on qT interval, demonstrating no 
significant effects on cardiac repolarization [73]. 
 
4.2 Brivaracetam for monotherapy in focal epilepsies 
 Two Phase III studies have just terminated (NO1276 and NO1306) and some partial 
results are available although none of them has been published yet. Both studies were double-
blind, randomized, multicentre, parallel group, historical-control conversion to monotherapy 
studies in patients with partial-onset seizures [74]. In both cases, patients were randomised to 
either BRV 50 mg or 100 mg for a 17-week evaluation period. These studies have been 
designed according to FDA regulations to obtain a monotherapy license in the US. 
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5. POST-MARKETING STUDIES  
 During recent years, a number of post-hoc pooled data analyses have been published. 
A large pooled analysis of all Phase IIb and Phase III studies and further additional open label 
and long-term follow up studies [75] confirmed seizure freedom rates of 4.9%, 4.2%, 3% and 
3.3% at 6, 12, 24 and 60 months respectively. This study included follow up data for more 
than 8 years in 41 patients showing a retention rate of 54% for more than 60 months [75]. A 
pooled data analysis [76] of three Phase III studies [69–71] investigating efficacy of BRV in 
focal seizures showed a mean seizure reduction of 19.5% for 50 mg, 24.4% for 100 mg and 
24% for 200 mg and seizure free rates of 2.5%, 5.1% and 4.0%. Another post-hoc analysis of 
pooled data [77] from three Phase II studies [69–71] looked at the effect of BRV in 
controlling secondarily GTCs (SGTCs). The median percentage reduction from baseline was 
66.6% for BRV 50 mg and almost one third of patients (30.4%) became seizure free from 
SGTCS during the 12-week treatment period for BRV >=50 mg. A post-hoc analysis of 
pooled data from the same three Phase III studies investigated efficacy in elderly patients 
(>65 years old) [78]. The authors reported efficacy and tolerability data very similar to those 
observed in the much larger overall pooled population but the sample size was made of only 
30 subjects. 
 
 Real life data on BRV come mainly from German groups who focused on efficacy 
and tolerability in highly drug-resistant patients and the possible dose-equivalence between 
LEV and BRV. A multicentre, retrospective cohort study in 262 patients with epilepsy 
followed up to a maximum of 12 months showed a retention rate of almost 80% at 3 months 
and 75.8% at six months with seizure free rates of almost 15% at 3 months and 15.3% at 6 
months [79]. The authors reported a TEAE rate of 37.8% but also pointed out that LEV-
associated behavioural problems improved upon switch to BRV in 57.1%, while LEV-
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associated somnolence improved in 70% of patients.  In this study a small subset of patients, 
around 7%, had idiopathic generalised epilepsy with no significant worsening in seizure 
pattern and frequency [79] further confirming the promising role of BRV in generalised 
epilepsies.  
A single centre retrospective study of BRV as adjunctive treatment in 101 patients with 
difficult to treat drug-resistant patients followed up to six months showed a retention rate of 
51.5% and a seizure free rate of 7% [80]. TEAEs were reported in around one third of 
patients. Interestingly they reported also a retention rate of 57% in those with no previous 
exposure to LEV.  
 
A few authors investigated specifically tolerability and safety of the rapid switch from LEV 
to BRV. In a German study  51 patients were switched with a ratio from 10:1 to 15:1 with no 
major problems [79]. Another German group report 43 cases of overnight LEV-BRV switch 
with no complications but a deterioration of seizures was observed in 5 cases [80]. An open-
label, prospective, phase IIIb exploratory study investigated the effect of a rapid switch from 
LEV to BRV in patients developing behavioural adverse events of LEV within 16 weeks of 
LEV initiation [81]. Among the 26 subjects who completed the study, during the 12 week 
observation period, 93.1% of patients reported a clinically meaningful reduction in 
behavioural adverse events [81]. 
 
6. CONCLUSIONS 
 BRV is a new AED currently licensed for the adjunctive treatment of adult patients 
with focal epilepsies and it is a ligand of the SV2A protein. The preclinical development of 
BRV is quite unique and has raised several doubts on current methodologies adopted for 
AED development, reinforcing the need for new approaches. The preclinical and clinical 
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profile suggest that BRV is potentially an ideal compound in the emergency setting given the 
rapid onset of action associated with being water soluble and, therefore, available in 
intravenous formulation. In addition, data from Phase III studies have already suggested that 
BRV may be effective not only in focal epilepsies but also in generalised syndromes. Further 
data from special populations such as children and women of child bearing age are urgently 
needed.  
 
7. EXPERT OPINION  
 BRV has shown an excellent antiepileptic activity in many experimental models of 
epilepsy and some promising properties as a disease modifying agent. Preclinical studies 
seem to suggest that BRV has a potentially greater efficacy as compared to LEV for its 
selective, high affinity, and different binding properties to SV2A, as well as a higher 
lipophilicity, correlating with a more rapid brain penetration in preclinical studies. However, 
there are no clinical studies supporting a greater efficacy of BRV over LEV and head to head 
comparison are needed to fully clarify this point. 
In terms of preclinical development, it has to be acknowledged that the developmental 
program of BRV is quite unique. The role of SV2A is far from being completely understood, 
however, the demonstration of a correlation between the SV2A binding affinity and the 
antiepileptic effect has driven a drug development strategy with a highly probability of 
success. The identification of the SV2A protein and the subsequent approach to preclinical 
epilepsy research represents a milestone which has impacted on this field and has 
considerable implications. In fact, the discovery of LEV efficacy despite its lack of effects on 
classical animal models commonly used to screen for new compounds has raised several 
doubts on current methodologies and increased the debate in this area of research. The 
established efficacy of BRV further reinforces this point and the need for new approaches. 
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The discovery of the SV2A protein and the subsequent development of BRV have further 
confirmed the impression that none of the new AEDs marketed during the last 20 years have 
improved the proportion of seizure free patients because current agents have been developed 
adopting the same animal models that were based on the same assumptions and theoretical 
bases. New and innovative preclinical models of epilepsy are urgently needed in order to 
explore new molecular targets.   
The preclinical and clinical profile of BRV clearly point out that it is probably the ideal AED 
to be used in an emergency setting given the rapid onset of action associated with being water 
soluble. Data on treatment of status epilepticus are currently just anecdotal and proper studies 
are needed. Data from patients with repetitive seizures and/or seizure clusters would be also 
of great interest.   
The monotherapy license may represent the future of BRV.  Emerging data are suggesting 
that the overnight conversion from LEV to BRV is not only safe and well tolerated but may 
provide further benefits in terms of tolerability especially in patients with paradoxical 
sedation from LEV or behavioural adverse events. Further data from larger samples are 
needed. Data from preclinical studies are also suggesting that BRV may be effective not only 
in focal epilepsies but may represent an alternative option in primary generalised syndromes 
and preliminary data from phase III and IV studies seem to confirm that. Drug options in 
generalised syndromes are still very limited and new drugs with a large spectrum of activity 
in both focal and generalised syndromes are more warranted. In this regard, data on safety 
from special populations such as children and women of child baring age are urgently 
needed.  
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Table 1. Spectrum of activity of Brivaracetam and Levetiracetam on different 
preclinical models of epilepsy. 
Model Brivaracetam Levetiracetam References 
Amygdala-kindled 
mice 
Reduced dose-dependently the 
seizure severity 
Complete suppression of seizures 
(at the highest tested dose). 
 
Reduced the duration of the 
afterdischarge. 
Limited protection even at the 
highest tested dose. 
 
 
 
No effects on this parameter. 
[28] 
 
Fully amygdala-kindled 
rats 
Suppressed motor seizure severity 
from low doses 
 
Reduced the after-discharge 
duration at the highest dose tested  
Similar effect from high doses 
 
 
No effects on this parameter 
[32] 
Audiogenic seizure-
susceptible mice 
Potent and complete protection 
from clonic convulsions  
Lower protection from clonic 
convulsions at high doses 
[32] 
GAERS 
Decreased SWDs from low doses 
 
 
Complete inhibition of the SWDs 
appearance at the highest dose 
Same decrease of SWDs but 
from higher doses 
 
No complete inhibition of 
SWDs, even at the highest tested 
dose. 
[32] 
MES 
Protection against tonic 
convulsions 
NO anticonvulsant activity [32] 
PTZ 
Protection against clonic 
convulsions 
NO anticonvulsant activity [32] 
Cardiac arrest-induced 
post-hypoxic myoclonus 
in rats 
Abolished post-hypoxic seizures 
at all doses 
Abolished post-hypoxic seizures 
only at higher doses 
[44] 
SSSE 
Shortened the cumulative 
duration of active seizures in a 
dose-dependent manner 
 
Reduced the number of chronic 
seizures occurring both at 6 
weeks and 1 year after SE 
Less reduction of cumulative 
seizures duration and only at the 
highest dose 
 
No effects 
 
[40] 
6-Hz corneal-kindling 
Protected from secondarily 
generalized motor seizures 
 
Pre-treatment suppressed kindling 
development 
 
Reduced the generalized motor 
seizures during wash-out period 
Same effect but at 
concentrations several-time 
higher 
 
Same effect but at doses 10 
times higher 
 
No effects 
 
[40] 
GAERS = Genetic Absence Epilepsy Rats from Strasbourg; MES = Maximal electroshock; PTZ = 
Pentylenetetrazol; SSSE = Self-sustaining status epilepticus 
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Table 2. Pharmacokinetics of Brivaracetam and Levetiracetam. 
 
 
 
 
  
 Brivaracetam Levetiracetam 
Absorption Rapidly and almost-completely 
absorbed (about 100%) 
Rapidly and almost-
completely absorbed (>95%)  
No food interaction 
Bioavailability 100% >95% 
T max after single 
dose 
1 -2h 1.3h 
Time to steady 
state 
after 48h 24–48h 
Protein binding <20% <10% 
Volume 
distribution 
0.6 L/kg 0.5 - 0.7 L/kg 
Metabolism Extensively metabolized: 
60% by hydrolysis independent of the 
cytochrome P450 
 
30% by hydroxylation   mediated by 
CYP2C19 
Minimal 
Not dependent on the hepatic 
CYP system 
Inactive 
metabolites 
acid, hydroxy, and 
hydroxy-acid derivatives 
L057 
Half-life 7–8 h 6–8h 
Clearance 0.06 mL/min/kg 0.6 mL/min/kg 
Elimination Renal primarily by metabolism 
8.6% unchanged drug; 
the rest as inactive metabolites 
66% as parent drug, 24% as 
L057 
Interactions Carbamazepine 
Phenytoin 
Phenobarbital/Primidone. 
Rifampin 
Oral contraceptives 
No pharmacokinetic 
interactions 
30 
 
Table 3. Efficacy results for Phase II and Phase III studies of Brivaracetam as 
adjunctive treatment in adults with focal epilepsies (median percentage reduction from 
baseline in POS frequency/week during the treatment period). 
                     Phase IIb Phase III 
 NO1193 NO1114 NO1252 NO1253 NO1254
§
 NO1258
#
 
Placebo 21.7% 16.3% 17.0% 17.8% 18.9% 17.6% 
5 mg  29.9% - - 20.0%  
 
26.9% 
- 
20 mg  42.6% - 30.0% 22.5% - 
50 mg  *53.1% 34.9% 26.8% *30.5% - 
100 mg  - - *32.5% - *37.2% 
150 mg - 28.3% - - - 
200 mg - - - -  *35.6% 
 *statistically significant; 
§
Flexible-dose study (BRV 20-150 mg); 
#
not primary endpoint 
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Figure Legend Figure 1. Brivaracetam 
 
 
 
 
 
